

This is a repository copy of *Exploratory study of MYD88 L265P*, rare NLRP3 variants and clonal hematopoiesis prevalence in patients with Schnitzler's Syndrome..

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/148254/

Version: Accepted Version

Article:

Pathak, S, Rowczenio, DM, Owen, RG et al. (9 more authors) (2019) Exploratory study of MYD88 L265P, rare NLRP3 variants and clonal hematopoiesis prevalence in patients with Schnitzler's Syndrome. Arthritis and Rheumatology, 71 (12). pp. 2121-2125. ISSN 2326-5191

https://doi.org/10.1002/art.41030

© 2019, American College of Rheumatology. This is the post-peer reviewed version of the following article: Pathak, S., Rowczenio, D. M., Owen, R. G., Doody, G. M., Newton, D. J., Taylor, C., Taylor, J., Cargo, C., Hawkins, P. N., Krause, K., Lachmann, H. J. and Savic, S. (2019), Exploratory Study of MYD88 L265P, Rare NLRP3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome. Arthritis Rheumatol, 71: 2121-2125, which has been published in final form at https://doi.org/10.1002/art.41030. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Patient® number®	Sex⊞	Age@at@symptom@ onset@	Para-protein⊠	lgMk@para-protein⊠ levels⊠(g/l)⊠	Response@to@L-1@ inhibition@	Bone@marrow@histology@	Genes/Variants@dentified@by@MDS@panel@ Prediction/VAF@	MYD88@1265P?@	NLRP3@mutationa status stat	III XIInactivation@esulti(if@applicable
12	male⊡	622	lgMk®	6₽	complete	No@overt@LPL@	T	Yes®	2	-17
22	female₫	43.52	IgMk®	17🛚	good@	No@bvert@LPL@		Yes⊡	2	random®
32	male⊡	51.5₪	IgMk®	82	good@	No@overt@LPL@		Yes⊡	2	-17
42	male∄	672	IgMk∄	82	complete	No@bvert@LPL@		Yes⊡	2	-2
5₹	female∄	54.52	IgM k∄	3₽	good⊡	No@overt@LPL@		No∄	2	random⊞
6 2	female®	72.52	IgM k∄	117	complete	No@bvert@LPL@		No⊡	2	random∄
72	female⊞	55.5᠌	IgMk®	5₪	complete⊞	No@bvert@LPL@		No	2	random∄
82	female⊞	532	IgMk⊡	5₪	complete⊞	No@bvert@LPL@		No	2	random⊞
92	female⊞	60∄	IgGk®	N/A∄	good®	Low-grade@myeloma@		No	2	non-random skewed 80%
10⊠	female®	72.5᠌	lgMk⊡	32	good∄	No@bvert@LPL®	7	No	Q703K*₪	-2
112	male	622	lgMk2	32	good∄	No@bvert@LPL@		Yes∄	2	-
12🛚	male	36.82	lgMk⊡	32	Partial	No@bvert@LPL@	2	No	<u> </u>	
132	female™	37.9₺	IgMk⊞	37	complete	No@bvert@LPL@		No	2	random®
142	male®	43.92	lgGλ⊞	N/AE	complete®	15%BMplasmattell		No∄	2	-2
15E	female®	44.82	IgMk®	17	complete 2	No@overt@LPL@		No∄	2	random®
162	female®	49.6₽	IgMk®	42	complete⊡	not@done@	D	No∄	2	random®
17🛽	male®	49.9ಔ	IgMk⊠	92	complete⊞	No@bvert@LPL@		No®	2	-2
182	male⊡	52.82	IgMλ@(IF)₪	N/A2	complete	No@bvert@LPL@		No®	2	-2
19🛚	male®	57.1₪	IgMk⊡	7₽	complete⊞	LPL®		Yes⊞	V198M*∄	-2
20∄	male∄	58.1₪	lgMk∄	3∄	complete ∄	LPL®	STAG-200t.559C>T0p.GIn187*0 Predicted:0pathogenic0VAF:00.0810	No	2	-17
21🛚	male®	59.6₫	lgMλ⊡	7∄	died@before@ treatment@	No@vert@LPL@	E .	No	2	-17
22🗉	male	61.72	IgMκℤ	52	complete	No@bvert@LPL@		No®	2	-B
231	female⊞	60.7₪	lgMk∄	9∄	complete	low@grade@marginal@one@ lymphoma@	100	No	2	random 🛚
24🛚	female⊡	68.4∄	IgMk∄	8₽	complete⊞	No@bvert@LPL@		No	2	random⊡
25₪	male⊡	78.9ℤ	IgMkℤ	7₪	complete	No@bvert@LPL@		Yest	2	-2
26᠌	female⊞	39.7ℤ	IgMkℤ	16₪	complete®	No@bvert@LPL@	7	No∄	2	random®
27🛭	male⊡	40.7ℤ	IgMkℤ	4₽	complete®	No@bvert@LPL@		No∄	2	-2
28∄	male⊡	61.2᠌	IgMk®	82	complete®	No®bvert®LPL®	7	No®	2	-2
29ಔ	male∄	43.6₪	IgMk®	6₽	complete®	MGUS®	7	Yes⊡	2	-12
30ℤ	female₫	59⊉	lgMkℤ	5₪	complete⊞	MarginalZoneLymphoma2		Yes⊡	2	random⊡
CAPS#11	male®	48∄	N/AE	N/A2	complete⊞	N/A2		No	E567K型	-B
CAPS B 2	male®	792	N/A2	N/A∑	complete⊞	N/AI		No∄	G569V2	-12
CAPSBES TO	female⊞	67₾	N/A@	N/A®	complete⊞	N/A®	DNMT3-42隆.2645G>A頃.Arg882His [®] Predicted:即athogenic®/AF:即.407 [®] 『 TET-2隆.4585C>T即.Gln1529* [®] Predicted:即athogenic®/AF:0.388 [®] 『 TET-2頃.Gln1699* [®] Predicted:即athogenic®/AF:0.402 [®]	Noß	A352Tm	non-random卧&kewed頃80%
CAPSB 42	male⊡	63ℤ	N/A®	N/AE	complete	N/AE	T T T T T T T T T T T T T T T T T T T	No	Y563C∄	-2
CAPS®-55	female∑	62₫	N/A2	N/AE	complete	N/AE		No⊡	Y563C₹	random®
CAPS 15 18	female⊞	2	N/AE	N/A2	complete⊞	N/AE	7	NoE	Y536C∄	random⊞

Table 1: Clinical and laboratory findings of 30 SchS patients and 6 CAPS patients LPL = lymphoproliferative lymphoma IF: immunofluorescence VUS: variant of unknown significance

^{*}common non-pathogenic NLRP3 variants unlikely to be disease causative and have shown to be present in healthy individuals